Hancock Story

<div class='circular--portrait' style='background:#008000;color: #FFE4E1;font-size:4em;'>HJ</div>
HJLI -- USA Stock  

USD 5.82  0.15  2.51%

Hancock Jaffe Current Ratio is most likely to increase slightly in the upcoming years. The last year's value of Current Ratio was reported at 0.76. The current Debt to Equity Ratio is estimated to increase to 2.66, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (7.9 M). The stock just had it stock split. Hancock Jaffe has reported 1 for 25 split on 30th of November 2020. Although many conservative investors are getting more into healthcare space, we should study Hancock Jaffe's current fundamentals in more details. We will evaluate why we are still confident in anticipation of a recovery. Will stockholders continue to hold, or should we expect a sell-off?
Published over three months ago
View all stories for Hancock Jaffe | View All Stories
Should you pay attention to changing Hancock Jaffe (NASDAQ:HJLI) fundamentals?
Hancock Jaffe is UNDERVALUED at 14.54 per share with modest projections ahead. We consider Hancock Jaffe slightly risky. Hancock Jaffe Labora holds Efficiency (Sharpe) Ratio of 0.0243, which attests that the entity had 0.0243% of return per unit of risk over the last month. Our standpoint towards determining the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-seven technical indicators for Hancock Jaffe Labora, which you can use to evaluate future volatility of the firm. Please check out Hancock Jaffe Downside Deviation of 4.2, market risk adjusted performance of 0.239, and Risk Adjusted Performance of 0.0365 to validate if the risk estimate we provide is consistent with the expected return of 0.16%.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Hancock Jaffe income statement, its balance sheet, and the statement of cash flows. Potential Hancock Jaffe investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Hancock Jaffe investors may use each financial statement separately, they are all related. The changes in Hancock Jaffe's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Hancock Jaffe's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Hancock Jaffe fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Hancock Jaffe performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Hancock Jaffe shares is the value that is considered the true value of the share. If the intrinsic value of Hancock is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Hancock Jaffe.
Please read more on our fundamental analysis page.

Are Hancock Jaffe Earnings Expected to grow?

The future earnings power of Hancock Jaffe involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Hancock Jaffe factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Hancock Jaffe stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Hancock expected earnings.

How Hancock utilizes its cash?

To perform a cash flow analysis of Hancock Jaffe, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Hancock Jaffe is receiving and how much cash it distributes out in a given period. The Hancock Jaffe cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Hancock Jaffe Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (7.68 Million)

Hancock Jaffe Gross Profit

Hancock Jaffe Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Hancock Jaffe previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Hancock Jaffe Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Acquisition by Glynn Craig of 324000 shares of Hancock Jaffe subject to Rule 16b-3

Legal trades by Hancock Jaffe insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Hancock insider trading alert for grant of stock option by Glynn Craig, Chief Financial Officer, on 23rd of February 2021. This event was filed by Hancock Jaffe Laboratorie with SEC on 2021-02-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Hancock Jaffe Labora

The modest gains experienced by current holders of Hancock Jaffe Laboratories may raise some interest from stockholders. The stock closed today at a share price of 11.54 on 19,595,600 in trading volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 30 days investing horizon is currently 6.62. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Hancock Jaffe Laboratories partners.

Asset Utilization

One of the ways to look at asset utilization of Hancock is to check how much profit was generated for every dollar of assets it reports. Hancock Jaffe retains a negative application of resources of -65.33 (percent), losing $0.65 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Hancock Jaffe Laboratories shows how discouraging it operates for each dollar spent on its resources.

Current Assets
1.4 M
Assets Non Current
Current Assets1.45 Million35.0
Assets Non Current1.95 Million47.16

Our perspective of the current Hancock Jaffe rise

The skewness is down to 3.87 as of today. As of the 12th of December 2020, Hancock Jaffe retains the Risk Adjusted Performance of 0.0365, downside deviation of 4.2, and Market Risk Adjusted Performance of 0.239. Hancock Jaffe technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Hancock Jaffe Labora, which can be compared to its competitors. Please check out Hancock Jaffe Labora jensen alpha, as well as the relationship between the potential upside and skewness to decide if Hancock Jaffe is priced fairly, providing market reflects its last-minute price of 11.54 per share. Given that Hancock Jaffe Laboratories has jensen alpha of 0.0766, we strongly advise you to confirm Hancock Jaffe Labora's regular market performance to make sure the company can sustain itself at a future point.

The Current Takeaway on Hancock Jaffe Investment

While some firms under the medical devices industry are still a bit expensive, Hancock Jaffe may offer a potential longer-term growth to stockholders. To conclude, as of the 12th of December 2020, we believe that Hancock Jaffe is currently undervalued with very high chance of distress in the next two years. However, our present 30 days buy-sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Hancock Jaffe Laboratories. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com